The largest community of pharma leaders

Cerevel Therapeutics Announces First Patient Dosed in Phase 2 Trial of CVL-865, an Investigational Therapy in Development for the Treatment of Epilepsy

BOSTON–(BUSINESS WIRE)–Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced dose administration for the first patient in the Phase 2 REALIZE trial of CVL-865, an orally-administered investigational therapy currently in development as an adjunctive treatment in adults with drug-resistant focal onset seizures, the most prevalent seizure disorder in epilepsy. “Nearly one-third of people experiencing focal onset seizure


Recent Articles